Press release
Huntingtons Disease Therapeutics Market to Witness Comprehensive Growth by 2021
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3730
Huntington’s disease usually causes psychiatric, cognitive and movement disorders with a variety of signs and symptoms. Cognitive disorders associated with Huntington’s disease include lackof flexibility, difficulties in learning and lack of impulse control that can result in sexual promiscuity. Movement disorders associated with Huntington’s disease includes muscle problems, abnormal eye movements and difficulties with the physical production of speech and swallowing. The most common psychiatric disorder associated with Huntington’s disease is depression.Depression appears due to the injury of the brain and subsequent changes in brain function.
To overcome this problem, medications are available to manage the symptoms of Huntington’s disease; however treatments can’t prevent the mental, physical and behavioral disabilities associated with the condition.
In terms of geographic, North America dominates the global Huntington’s disease therapeutics market. This is due to increased awareness about this disease in the region. The U.S. represents the largest market for Huntington’s disease therapeutics followed by Canada in North America. In Europe, Germany, France and the U.K. holds major share of Huntington’s disease therapeutics market. However, Asia is expected to show high growth rates in the next five years in global Huntington’s disease therapeutics market. This is due to many companies constructing their manufacturing facilities in the region. In addition, increasing awareness about Huntington’s disease is also supporting in the growth of the market in the region. Japan, China and India are expected to be the fastest growing Huntington’s disease therapeutics markets in Asia.
In recent time, unmet medical need is key driver of the global Huntington’s disease therapeutics market. Increased pharmaceutical R&D investment and introduction of innovative drugs have also fueled the growth of global Huntington’s disease therapeutics market. This is due to less number of curative drugs has led manufacturers to increase investment in R&D for development of innovative solutions to treat Huntington’s disease. Extensive pipeline drugs with properties, such as high patient compliance and improved safety, is also supporting in the growth of global Huntington’s disease therapeutics market. Alternative therapies, such as psychotherapy, speech therapy and physiotherapy hold immense potential to the growth of global Huntington’s disease therapeutics market.
However, stringent regulations hamper the growth of global Huntington’s disease therapeutics market. Moreover, less number of approved drugs for the treatment of Huntington’s disease also obstructs the growth of the market. Increasing mergers and acquisitions between drug manufacturing companies is key trend of global Huntington’s disease therapeutics market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3730
Some of the major companies operating in the global Huntington’s disease therapeutics market are Valeant Pharmaceuticals International Inc., Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros and Ipsen.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Huntingtons Disease Therapeutics Market to Witness Comprehensive Growth by 2021 here
News-ID: 513276 • Views: …
More Releases from Persistence Market Research Pvt. Ltd
Innovative Rehabilitation Technologies Drive Growth in Stroke Rehabilitation Mar …
Stroke Rehabilitation Market Size
The global stroke rehabilitation market size was valued at US$ 266.4 million in 2021 and is expected to grow at a CAGR of 9% from 2022 to 2032. Revenue generated from the sales of stroke rehabilitation solutions will surge to US$ 679.6 Million by the end of 2032.
The growth of the market is being driven by the increasing incidence of strokes, the growing demand for innovative rehabilitation…
Launch of New Laser-Based Devices by Key Players Fueling Growth of Global Aesthe …
Market Study on Aesthetic Lasers
The aesthetic lasers market reached US$2.8 billion in global revenue in 2021, and it will continue to expand quickly, with a value CAGR of 6.4%, to reach US$5.5 billion by the end of 2032. The growth of the market is being driven by the increasing demand for minimally invasive cosmetic procedures, rising disposable income, technological advancements, and growing medical tourism.
Stay Ahead with Market Intelligence Get Free…
Predictive Insights for Precision Medicine: The Global Biosimulation Market is S …
Biosimulation Market Research
The Global Biosimulation Market Size was valued at USD 2.9 billion in 2022 and is expected to reach USD 10.0 billion by 2030, registering a CAGR of 16.9% during the forecast period. The growth of the biosimulation market is being driven by the increasing use of biosimulation in a variety of applications, such as drug discovery, clinical trials, and toxicity prediction.
Market Overview
The biosimulation market has experienced rapid growth…
Wheelchair and Components Market: Growing Demand for Lightweight and Smart Wheel …
Wheelchair and Components Market
The global wheelchair and components market is projected to reach USD 17.9 billion by 2033, at a CAGR of 3.7% from 2022-2033. The growth of the market is driven by the increasing prevalence of disabilities, the rising geriatric population, and technological advancements in wheelchair design and manufacturing.
Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/12961
The global wheelchair and components market has witnessed significant growth in…
More Releases for Huntington’s
Why is Presence of Huge Middle-Aged Population Driving Huntington’s Disease Ge …
The global Huntington’s disease (HD) genetic testing market is predicted to generate a revenue of $28.3 million by 2030, increasing from $20.6 million in 2019, progressing at a 3.1% CAGR during the forecast period (2020–2030), as per a research conducted by P&S Intelligence. The presence of a large middle-aged population, reducing costs of genetic tests, initiatives taken by private and public organizations for raising awareness regarding HD, and reducing costs…
Huntington’s Disease Treatment Market 2021 Competitive Landscape, Future Trend …
Precision Business Insights published a research report on "Huntington Disease Treatment Market By Drug Class (Anticonvulsants, Antidepressants, Antidopaminergics, Antipsychotics), Route Of Administration (Oral, Parenteral), Distribution Channel (Hospitals pharmacies, Retail pharmacies, Online pharmacies) And Geography - Global/Region/Country Forecast to 2027".
Huntington's disorder is a hereditary condition in which nerve cells in the central nervous system degenerate (CNS). The condition has a wide influence on a person's functioning skills, generally resulting in…
Huntington’s Disease Treatment Market Share, Applications with Top Players Ver …
Huntington's disease, also known as Huntington's chorea, is an autosomal dominant inherited rare disorder that causes progressive degeneration of nerve cell of brain leading to deterioration of a person’s physical and mental abilities. Huntington's disease symptoms usually are detected at the age of 30–50 and gets worse over 10 to 25 year period from the onset of disease. Huntington's disease is usually associated with movement disorders, cognitive disorders or psychiatric…
Huntington’s Disease Treatment Market Worldwide Top Players Revenue and Foreca …
Huntington's disease, also known as Huntington's chorea, is an autosomal dominant inherited rare disorder that causes progressive degeneration of nerve cell of brain leading to deterioration of a person’s physical and mental abilities. Huntington's disease symptoms usually are detected at the age of 30–50 and gets worse over 10 to 25 year period from the onset of disease. Huntington's disease is usually associated with movement disorders, cognitive disorders or psychiatric…
Huntington’s Disease Therapeutics Market Segmentation and Major Players Analys …
Huntington’s disease (HD) is an autosomal dominant hereditary disorder of the central nervous system. The disease results in progressive degeneration of the brain cells. A physician named George Huntington described the disorder in detail as hereditary chorea in 1872. Thus, earlier it was known as Huntington’s chorea or HC. Huntington’s disease usually develops symptoms in adulthood between the age of 30 years and 40 years. In case the symptoms of…
Huntington’s Disease Therapeutics Market: Emerging Trends and New Technologies …
Huntington’s disease (HD) is an autosomal dominant hereditary disorder of the central nervous system. The disease results in progressive degeneration of the brain cells. A physician named George Huntington described the disorder in detail as hereditary chorea in 1872. Thus, earlier it was known as Huntington’s chorea or HC. Huntington’s disease usually develops symptoms in adulthood between the age of 30 years and 40 years. In case the symptoms of…
